Inferra AI / Company / BSX / Slides
Boston Scientific — Presentation (company IR deck)
Boston Scientific (BSX) · 17 slides · Filed Oct 28, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All BSX deck slides
Slide 1 — Enduring Growth
Relentless Innovation Enduring Growth ACC 2026 Investor Update March 28, 2026
Slide 2 — Enduring Growth
Relentless Innovation Enduring Growth Dr. Ken Stein| Senior Vice President & Chief Medical Officer
Slide 3 — The Cardiovascular group
The Cardiovascular group Therapies that treat millions of patients worldwide each year Cardiac Rhythm Management and Diagnostics (CRMDx) WATCHMAN (WM) Electro- physiology (EP) Interventional Oncology & Embolization (IO&E) Interventional Cardiology (IC) Vascular Therapies (VT) Atrial Fibrillation (AF) Solutions Interventional Cardiology & Vascular Therapies (ICVT) Advancing meaningful innovation to address disease states affecting over a billion people globally
Slide 4 — Driving evidence generation to fill clinical gaps
ICVT WM CRM EP IO&E 2026E 2027E 2028E+ FRACTURE (H1: 26) Coronary IVL IDE to support SEISMIQ approval CHAMPION-AF WATCHMAN as first-line therapy vs. OAC AVANT GUARD FARAPULSE PFA first-line therapy in persistent patients SIMPLAAFY Post-implant drug regimen LAAOS-IV Highest risk stroke patients with WATCHMAN + OAC OPTION-A WM + FP in Asia REMATCH-AF Redo persistent cases w/ FARAWAVE & FARAPOINT ROWAN TheraSphere combination therapy THRIVE TIVUS RDN for treatment of hypertension AGENT DCB STANCE AGENT DCB compared to standard of care for de novo coronary lesions VITALYST HR-PCI IDE To support U.S. approval LUX ORACLE New diagnostic insertable for HFpEF patients FARADIGM 1 & 2 IDE To support approval of FARAFLEX OPTIMIZE-PF Integration of Cortex + Opal MANDARIN TheraSphere in China SYNCHRONICITY CRT vs. CSP in left bundle branch patients Timeline represents expected presentation of data. Driving evidence generation to fill clinical gaps Consistent cadence of data releases over long-range plan (LRP) & beyond Data release supports: Product approval TAM expanding ELITE AF To support U.S. FDA approval ReDefine AF Cortex + FARAFLEX redo trial 4 HI-PEITHO EKOS vs. standard of care for pulmonary embolism Complex and non-AF market expansion data
Slide 5 — Enduring Growth
Relentless Innovation Enduring Growth Dr. Michael R. Jaff| Vice President & Chief Medical Officer, Vascular Therapies
Slide 6 — >90%
HI-PEITHO Clinical Trial Prospective, multicenter, global randomized controlled trial 6 544 patients with intermediate-risk pulmonary embolism (PE) at 59 sites in the U.S. and Europe EKOS Endovascular System + anticoagulation Anticoagulation alone >90% of patients in the emergency department receive anticoagulation alone3 ~1M people in the U.S. and Europe who are affected by PE annually1 >30% of hospitalized patients with PE are considered intermediate risk2 Primary outcome = 7-day composite of: • PE-related mortality • Cardiorespiratory decompensation or collapse • PE recurrence 1Wood KE et al. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877-905 2Giri J , Sista A , Weinberg I , et al. Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation 2019;140:774-801. 3Hsu SH, Ko CH, Chou EH, et al. Epidemiology of pulmonary embolism diagnosis and management among United States emergency departments over an eight-year period. Am J Emerg Med. 2024.
Slide 7 — Met primary efficacy endpoint
Met primary efficacy endpoint 7 1ISTH: International Society on Thrombosis and Haemostasis Potential Updates to PE Guidelines More Informed Clinical Decision-Making Data Presentation & Publication Patients treated with the EKOS system experienced 61% fewer primary endpoint events Major bleeding rate difference not statistically significant at 7- and 30- days between the two arms No intracerebral hemorrhagic events in either arm
Slide 8 — Enduring Growth
Relentless Innovation Enduring Growth Dr. Brad Sutton| Chief Medical Officer, AF Solutions
Slide 9 — ~40%
CHAMPION-AF Clinical Trial Largest trial comparing LAAC to NOACs as first-line therapy for stroke risk reduction in NVAF patients 9 Patient Population: 3,000 Randomized at 141 sites globally • Patients with non-valvular atrial fibrillation and deemed suitable for oral anticoagulation • CHA2DS2-VASc score of ≥2 for males or ≥3 for females Primary efficacy Primary safety Secondary safety Secondary net clinical benefit 0 3y 5y 4m Imaging WATCHMAN FLX ASA for 12mo (duration of trial recommended) Oral Anticoagulation NOAC per label for duration of trial 3mo NOAC±ASA or DAPT Primary efficacy: thromboembolic protection Secondary safety Secondary net clinical benefit 90% of heart-related blood clots form in the LAA in patients with NVAF3 ~60M people worldwide who are affected by atrial fibrillation (AF)1 5x higher stroke risk in patients with AF than people with normal heart rhythm2 1Linz, Dominik, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024 Feb 1:37:100786. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00205-3/fulltext. Accessed Feb. 3, 2026. 2FAQ About AFib. American Heart Association, Inc., 2023. https://www.heart.org/-/media/Files/Health-Topics/Atrial-Fibrillation/FAQ-About-AFib.pdf. Accessed Feb. 3, 2026. 3Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755-759. 4Tarn, D, Shih, K, Tseng, C. et al. Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients. JACC Adv. 2023 Jan, 2 (1) . https://doi.org/10.1016/j.jacadv.2022.100175 ~40% patients on OAC unprotected due to non-adherence4
Slide 10 — Met primary safety and efficacy endpoints
Met primary safety and efficacy endpoints 10 Cardiovascular death, stroke or systemic embolism Non-procedural bleeding (International Society on Thrombosis and Haemostasis [ISTH] major and modified clinically relevant non-major*) Primary Efficacy Endpoint: Met Non-Inferiority Primary Safety Endpoint: Met Superiority *Modified International Society on Thrombosis and Haemostasis (ISTH) clinically relevant non-major bleeding was defined as any sign or symptom of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for the ISTH definition of major bleeding but does meet at least one of the following criteria. • Requiring medical intervention by a healthcare professional • Leading to hospitalization or increased level of care (e.g., ER visit, diagnostic procedures, medication change) *1-sided 97.5% Z upper conf. bound = 2.6% KM Event Rate ± 1.5 SE; log-rank p-value KM Event Rate ± 1.5 SE
Slide 11 — 34%
All clinically meaningful bleeds (procedural and non-procedural) 11 34% Reduction in ISTH bleeding (including procedural) at 36 months KM Event Rate ± 1.5 SE
Slide 12 — Secondary endpoints underscore safety and net
Secondary endpoints underscore safety and net clinical benefit in WATCHMAN FLX arm 12 Net Clinical Benefit Endpoint: Met Superiority Secondary Safety Endpoint: Met Non-Inferiority ISTH major bleeding (procedural and non-procedural) Cardiovascular death, stroke, systemic embolism and non- procedural bleeding *1-sided 97.5% Z upper conf. bound = 1.2% KM Event Rate ± 1.5 SE
Slide 13 — 34%
CHAMPION-AF: All endpoints met 13 *Results from different clinical investigations are not directly comparable. Information provided for educational purposes only. CHAMPION-AF NOAC arm annualized ischemic stroke/SE rate: 0.7% 1Granger, C. Apixaban versus Warfarin in Patients with Atrial Fibrillation. NEJM 2011; 365(11):981-992 2Safari, Abdollah et al. Association Between Oral Anticoagulant Adherence and Serious Clinical Outcomes in Patients With Atrial Fibrillation: A Long‐Term Retrospective Cohort Study. JAHA. 2024 Sept, 13 (18). https://doi.org/10.1161/JAHA.124.035639 1.3% annualized stroke rate in ARISTOTLE seminal trial of Apixaban*1 Efficacy: Achieved non-inferiority 1.1% annualized stroke and systemic embolism rate in WATCHMAN FLX arm >87% patients who were medication adherent in the NOAC arm >50% increase in stroke risk for patients who are non-adherent to OACs2 34% Relative reduction in clinically meaningful bleeds procedural and non-procedural bleeding Safety: Achieved superiority 45% Despite enrolling a low-risk bleeding population, CHAMPION-AF demonstrated a significant reduction in procedural and non-procedural bleeding. Low Annualized Stroke Rate in CHAMPION-AF trial OAC Adherence is real-world challenge Relative reduction in non- procedural bleeding, including ISTH major and modified clinically relevant non-major bleeding Bleeding risk is a real concern for patients on OACs ARISTOTLE seminal trial Real-world data
Slide 14 — Positive data positions market for meaningful expansion
Expanded Reimbursement Guideline Evolution Positive data positions market for meaningful expansion 14 Published Literature & Labeling Update >$2.0B Market 5 million AF patients indicated ~$6.0B+ Market 20 million AF patients indicated 2030E+ Today Clinical trial results + sub-analyses Positive reimbursement through government and commercial payers 2028E+ 2026 Data supports market growth of ~20% through the LRP
Slide 15 — Fueling the future of LAAC innovation
▪ WATCHMAN Elite U.S. approval Fueling the future of LAAC innovation 4th generation built on the WM platform designed to enhance seal & address complex anatomy 15 2026E 2028E 2027E ▪ Initiate Elite AF Clinical Trial ▪ ACUNAV Luxera 4D ICE Catheter U.S. approval with WATCHMAN workflow ▪ Present SIMPLAAFY data ▪ Initiate OPTION-EMEA Clinical Trial OPTION-EMEA ▪ Present OPTION-A data (Asia) OPTION-A ▪ Concomitant Sheath U.S. approval * *Device under development. Not available for use or sale worldwide. ▪ Present ELITE AF data Engineered for consistent, durable seal across the broadest range of LAA anatomies
Slide 16 — Clinical Implications
Clinical Implications 16 “WATCHMAN FLX left atrial appendage closure may be considered as an alternative to NOACs in a shared decision- making process with atrial fibrillation patients who are deemed suitable for long-term oral anticoagulation!” – Dr. Saibal Kar, CHAMPION-AF coprincipal investigator Kar, S. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation: The CHAMPION-AF Clinical Trial. Presented at: the American College of Cardiology conference; March 28, 2026; New Orleans, LA.
Slide 17 — Enduring Growth
Relentless Innovation Enduring Growth Q&A 17